Vazkepa (Icosapent Ethyl)
Prescription omega-3 fatty acid for cardiovascular risk reduction
Vazkepa (icosapent ethyl) is a prescription medicine containing a highly purified omega-3 fatty acid derived from fish oil. It is used alongside statin therapy to reduce the risk of major cardiovascular events — including heart attack, stroke, and cardiovascular death — in adults with elevated triglycerides who have established cardiovascular disease or diabetes with additional risk factors. The landmark REDUCE-IT trial demonstrated a 25% reduction in cardiovascular events with Vazkepa.
Quick Facts: Vazkepa
Key Takeaways
- Vazkepa is a highly purified omega-3 fatty acid (EPA only) that reduces cardiovascular risk when added to statin therapy — it does not replace statins.
- The REDUCE-IT trial showed a 25% relative risk reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) with Vazkepa versus placebo.
- The standard dose is 2 capsules (998 mg each) taken twice daily with or after food, for a total daily dose of approximately 4 grams of icosapent ethyl.
- Common side effects include increased bleeding tendency and atrial fibrillation — patients on blood thinners should be monitored closely.
- Vazkepa contains soy lecithin and is derived from fish oil — it should not be used by patients with soy, peanut, or fish allergies without medical supervision.
What Is Vazkepa and What Is It Used For?
Vazkepa contains the active substance icosapent ethyl, which is the ethyl ester of eicosapentaenoic acid (EPA) — a highly purified omega-3 fatty acid obtained from fish oil. Unlike over-the-counter fish oil supplements that contain a mixture of EPA and DHA at varying purities, Vazkepa provides pharmaceutical-grade EPA in a controlled, consistent dosage form.
The primary function of Vazkepa is to lower triglyceride levels in the blood. Triglycerides are a type of fat that, when elevated, contribute to an increased risk of atherosclerotic cardiovascular disease. However, the cardiovascular benefits of Vazkepa extend beyond simple triglyceride reduction. Research suggests that icosapent ethyl also has anti-inflammatory, antiplatelet, and plaque-stabilizing properties that contribute to its cardioprotective effects.
Vazkepa is prescribed as an add-on therapy to statins (cholesterol-lowering medicines) to reduce the risk of cardiovascular events, including:
- Heart attack (myocardial infarction)
- Stroke
- Cardiovascular death
- Coronary revascularization (procedures to restore blood flow)
- Unstable angina requiring hospitalization
Specifically, Vazkepa is indicated for use in adults with elevated triglyceride levels (≥150 mg/dL or 1.7 mmol/L) who fall into one of two categories: those who already have established cardiovascular disease, or those with diabetes mellitus (type 1 or type 2) plus at least one additional cardiovascular risk factor. In both groups, patients must already be on maximally tolerated statin therapy.
Vazkepa is not the same as over-the-counter fish oil or omega-3 supplements. It contains a single, highly purified omega-3 fatty acid (EPA) at pharmaceutical-grade purity. The landmark REDUCE-IT trial demonstrated clear cardiovascular benefits for Vazkepa, while large-scale studies of mixed EPA/DHA supplements (such as the STRENGTH and VITAL trials) have not shown the same cardiovascular risk reduction.
What Should You Know Before Taking Vazkepa?
Before starting Vazkepa, your doctor will assess your overall health, current medications, and risk factors. It is essential to provide a complete medical history so your healthcare provider can determine whether Vazkepa is safe and appropriate for you. Below are the key considerations organized by category.
Contraindications
You should not take Vazkepa if:
- You are allergic to icosapent ethyl or any other ingredient in Vazkepa (see the composition section for a full list).
- You are allergic to soy or peanuts — Vazkepa capsules contain soy lecithin, which can cause severe allergic reactions in sensitized individuals.
Warnings and Precautions
Speak with your doctor or pharmacist before taking Vazkepa if any of the following apply to you:
- Fish or shellfish allergy: Since Vazkepa is derived from fish oil, patients with known fish or shellfish allergies should exercise caution. Your doctor will weigh the potential benefits against the risk of allergic reaction.
- Liver problems: Icosapent ethyl is metabolized by the liver. If you have hepatic impairment, your doctor may need to monitor your liver function tests during treatment.
- Atrial fibrillation or atrial flutter: Vazkepa has been associated with an increased risk of atrial fibrillation (irregular heartbeat) and atrial flutter. If you have a history of these conditions, your doctor should carefully assess whether the cardiovascular benefits outweigh this risk.
- Bleeding risk: Vazkepa may increase bleeding tendency. This risk is heightened if you also take anticoagulants (blood thinners such as warfarin), antiplatelet agents (such as aspirin or clopidogrel), or if you have an underlying bleeding disorder.
If you are taking anticoagulant or antiplatelet medications, your doctor will monitor your blood coagulation parameters during treatment with Vazkepa. Report any unusual bruising, prolonged bleeding from cuts, blood in urine or stool, or nosebleeds to your doctor promptly.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before taking Vazkepa. There is limited data on the use of icosapent ethyl during pregnancy, and it should generally not be used unless the potential benefits clearly outweigh the potential risks to the fetus.
Vazkepa should not be used during breastfeeding, as it is unknown whether icosapent ethyl or its metabolites pass into breast milk and what effects they may have on the nursing infant. Your doctor will help you evaluate the balance between the benefits of treatment and the potential risks to your child.
Regarding fertility, discuss any concerns with your healthcare provider during treatment, as comprehensive fertility data in humans is limited.
Children and Adolescents
Vazkepa has not been studied in children and adolescents under 18 years of age. It should not be given to this age group due to the lack of safety and efficacy data.
Important Information About Excipients
Vazkepa capsules contain several excipients that some patients may need to be aware of:
- Maltitol (E965): If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Vazkepa.
- Sorbitol (E420): Each capsule contains 83 mg of sorbitol, which is a source of fructose. Patients with hereditary fructose intolerance should not take Vazkepa without consulting their doctor.
- Soy lecithin: Do not use Vazkepa if you are allergic to soy or peanuts.
How Does Vazkepa Interact with Other Drugs?
While icosapent ethyl does not have a large number of pharmacokinetic drug interactions, it does have clinically significant pharmacodynamic interactions, particularly with medications that affect blood coagulation. Tell your doctor about all medicines you take, have recently taken, or plan to take.
Major Interactions
The most important drug interactions with Vazkepa involve medications that affect hemostasis (blood clotting). When combined with these drugs, Vazkepa's mild antiplatelet properties can lead to an additive increase in bleeding risk. Your doctor may need to monitor blood tests more frequently.
| Drug | Category | Effect | Management |
|---|---|---|---|
| Warfarin | Anticoagulant | Increased INR and bleeding risk | Monitor INR closely; dose adjustment may be needed |
| Rivaroxaban | DOAC | Increased bleeding risk | Monitor for signs of bleeding; clinical assessment |
| Apixaban | DOAC | Increased bleeding risk | Monitor for signs of bleeding |
| Clopidogrel | Antiplatelet | Additive antiplatelet effect | Monitor for bruising and bleeding |
| Aspirin (high dose) | Antiplatelet / NSAID | Additive antiplatelet effect | Monitor for signs of bleeding |
Minor Interactions
Vazkepa does not have significant interactions with most other common medications. It does not meaningfully affect cytochrome P450 enzymes, so interactions with drugs metabolized by these pathways are unlikely. However, you should always inform your doctor of all medications you are taking, including:
- Statins (these are meant to be taken together with Vazkepa)
- Other lipid-lowering agents (fibrates, ezetimibe)
- Antihypertensive medications
- Diabetes medications
- Herbal supplements, especially those with antiplatelet or anticoagulant properties (e.g., ginkgo biloba, garlic supplements, fish oil supplements)
If you are already taking over-the-counter fish oil or omega-3 supplements, discuss this with your doctor. Taking additional omega-3 products alongside Vazkepa is generally not recommended, as it may increase the risk of side effects, particularly bleeding, without providing additional cardiovascular benefit.
What Is the Correct Dosage of Vazkepa?
Always take Vazkepa exactly as your doctor has told you. Do not change your dose without speaking to your doctor first. The dosage is the same for all adult patients, regardless of triglyceride levels or body weight.
Adults
Standard Adult Dose
Dose: 2 capsules (998 mg each) taken twice daily
Total daily dose: 4 capsules = approximately 4 g icosapent ethyl
Administration: Take with or after a meal. Swallow capsules whole — do not open, crush, dissolve, or chew.
Taking Vazkepa with food is important for optimal absorption. The capsules should be swallowed whole to ensure proper delivery of the active ingredient. If you have difficulty swallowing capsules, discuss alternative options with your doctor or pharmacist.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (18+) | 2 × 998 mg capsules | Twice daily | Take with or after meals |
| Elderly (65+) | 2 × 998 mg capsules | Twice daily | No dose adjustment required |
| Children (<18) | Not recommended | N/A | Not studied in this population |
| Hepatic impairment | Standard dose | Twice daily | Liver function monitoring may be needed |
Elderly Patients
There is no need to adjust the dose for elderly patients aged 65 years and over. Clinical trial data, including the REDUCE-IT study, included a significant proportion of older patients and found no difference in safety or efficacy requiring dose modification. The standard recommended dose of 2 capsules twice daily applies equally to this population.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if you miss an entire day's doses, simply take your next scheduled dose as planned. Do not take a double dose to make up for a forgotten one. If you frequently forget doses, consider setting a reminder or asking your pharmacist about adherence strategies.
Overdose
If you accidentally take more capsules than prescribed, contact your doctor or pharmacist for advice. In clinical studies, doses up to 4 g daily were used, and the adverse effect profile at this dose is well characterized. Taking significantly more than prescribed could theoretically increase the risk of bleeding and gastrointestinal side effects. No specific antidote exists; management would be supportive and symptom-based.
Do not stop taking Vazkepa without consulting your doctor first. Discontinuation should be a shared decision between you and your healthcare provider, taking into account your overall cardiovascular risk profile and the reasons for stopping.
What Are the Side Effects of Vazkepa?
Like all medicines, Vazkepa can cause side effects, although not everyone gets them. Most side effects are mild to moderate in severity and do not require discontinuation of treatment. However, some side effects are serious and require prompt medical attention.
Serious Side Effects
Contact your doctor immediately if you experience any of the following:
- Heart palpitations or irregular heartbeat — these may be symptoms of atrial fibrillation, a common side effect (affecting up to 1 in 10 patients). While not immediately life-threatening, atrial fibrillation requires medical evaluation and may need treatment.
- Easy bruising or difficulty stopping bleeding — this is a very common side effect (affecting more than 1 in 10 patients). The bleeding risk increases if you are also taking blood-thinning medications.
Seek immediate medical help if you experience symptoms of a severe allergic reaction (hypersensitivity), which is uncommon (affecting up to 1 in 100 patients):
- Skin rash, itching, or hives
- Difficulty breathing or wheezing
- Tightness or itchy sensation in the throat
- Swollen lips, face, or tongue
- Abdominal pain, cramping, diarrhea, nausea, or vomiting
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Bleeding (increased tendency to bruise or bleed)
Common
May affect up to 1 in 10 people
- Atrial fibrillation or atrial flutter (irregular heartbeat)
- Peripheral edema (swelling of hands, arms, legs, and feet)
- Musculoskeletal pain (pain in muscles, bones, or joints)
- Gout (painful joint swelling due to uric acid buildup)
- Skin rash
- Constipation
- Eructation (burping/belching)
Uncommon
May affect up to 1 in 100 people
- Dysgeusia (bad or altered taste in the mouth)
- Hypersensitivity reactions (allergic reactions)
Frequency Not Known
Cannot be estimated from available data
- Oropharyngeal swelling (sore throat with swelling)
If you experience any side effects, including those not listed here, tell your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory agency (such as the EMA in Europe or the FDA in the United States). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Vazkepa?
Proper storage of Vazkepa is important to maintain the effectiveness and safety of the capsules throughout their shelf life. Follow these guidelines:
- Temperature: Store at or below 30°C (86°F). Do not freeze.
- Moisture protection: Vazkepa capsules are moisture-sensitive. If using bottles, keep the bottle tightly closed. If using blister packs, store in the original packaging.
- Expiry date: Check the expiry date (EXP) on the bottle label or blister pack. The expiry date refers to the last day of the stated month. Do not use Vazkepa after this date.
- Children: Keep this medicine out of the sight and reach of children at all times.
- Disposal: Do not throw unused medicines in the household waste or flush them down the drain. Return unused medicines to your pharmacist for safe disposal to protect the environment.
Vazkepa is available in two packaging formats. Bottles are white 300 mL HDPE containers with a child-resistant closure, containing 120 capsules each. Blister packs contain 4×2 capsules in perforated unit-dose blisters made of PVC/PCTFE/aluminium. Pack sizes include single-bottle or three-bottle cartons.
What Does Vazkepa Contain?
Understanding what is in your medicine can help you identify potential allergens and make informed decisions about your treatment. Each Vazkepa soft capsule contains the following:
Active Ingredient
Icosapent ethyl 998 mg — this is the ethyl ester of eicosapentaenoic acid (EPA), a highly purified omega-3 fatty acid derived from fish oil. Each capsule delivers a standardized, pharmaceutical-grade dose.
Inactive Ingredients (Excipients)
- Capsule fill: all-rac-alpha-tocopherol (vitamin E, used as an antioxidant to prevent degradation)
- Capsule shell: gelatin, glycerol, maltitol liquid (E965), sorbitol liquid non-crystallising (E420), purified water, and soy lecithin
- Printing ink: titanium dioxide, propylene glycol, hypromellose
Physical Description
Vazkepa capsules are oblong, soft capsules measuring approximately 25 × 10 mm. They have a light yellow to amber-colored shell containing a colorless to pale yellow liquid inside. Each capsule is embossed with "IPE" in white ink for identification.
Manufacturer
Vazkepa is manufactured by MIAS Pharma Limited, Dublin, Ireland, and marketed by Amarin Pharmaceuticals Ireland Limited. The medicine is approved by the European Medicines Agency (EMA) for use throughout the European Union.
How Does Vazkepa Work in the Body?
The mechanism of action of icosapent ethyl is multifaceted and extends well beyond simple triglyceride lowering. After oral administration, icosapent ethyl is de-esterified to its active metabolite, eicosapentaenoic acid (EPA), which is then incorporated into cell membranes, lipoproteins, and various tissues throughout the body.
Triglyceride reduction: EPA reduces hepatic (liver) synthesis and secretion of very-low-density lipoprotein triglycerides (VLDL-TG). It also enhances triglyceride clearance from circulating VLDL particles by activating lipoprotein lipase. In clinical studies, Vazkepa reduced triglyceride levels by approximately 18% compared to placebo.
Anti-inflammatory effects: EPA competes with arachidonic acid in cyclooxygenase and lipoxygenase pathways, leading to the production of less inflammatory eicosanoids. EPA also gives rise to specialized pro-resolving mediators (SPMs) such as resolvins, which actively help resolve inflammation. This anti-inflammatory action is believed to be a major contributor to the cardiovascular benefits observed in the REDUCE-IT trial.
Plaque stabilization: EPA accumulates in atherosclerotic plaques, where it may improve plaque morphology by reducing the lipid-rich necrotic core, decreasing macrophage infiltration, and strengthening the fibrous cap. This can reduce the likelihood of plaque rupture, which is the proximate cause of most heart attacks and many strokes.
Antiplatelet and antithrombotic effects: EPA inhibits platelet aggregation through multiple pathways, including reduced thromboxane A2 production and enhanced prostacyclin synthesis. While these effects contribute to cardiovascular protection, they also explain the increased bleeding tendency observed with Vazkepa.
Membrane effects: EPA is incorporated into cell membranes, where it can modulate ion channel function, potentially reducing susceptibility to cardiac arrhythmias. However, the clinical significance of this effect is nuanced, given the observed increase in atrial fibrillation with Vazkepa use.
What Is the Clinical Evidence for Vazkepa?
The clinical evidence supporting Vazkepa is primarily derived from the REDUCE-IT trial (Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial), which is one of the most significant cardiovascular outcome trials in recent years.
The REDUCE-IT trial was a randomized, double-blind, placebo-controlled, multicenter study involving 8,179 patients across 11 countries. Participants were adults with established cardiovascular disease or diabetes with additional risk factors, elevated triglycerides (135–499 mg/dL), and well-controlled LDL cholesterol on statin therapy. They were randomly assigned to receive either icosapent ethyl 2 g twice daily or a mineral oil placebo.
After a median follow-up of 4.9 years, the trial reported the following key findings:
- Primary endpoint: A 25% relative risk reduction in the composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina (HR 0.75; 95% CI 0.68–0.83; p < 0.001).
- Key secondary endpoint: A 26% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.74; 95% CI 0.65–0.83; p < 0.001).
- Total events: A 30% reduction in total (first and subsequent) ischemic events.
- Cardiovascular death: A 20% relative risk reduction (HR 0.80; 95% CI 0.66–0.98; p = 0.03).
These results led to the approval of Vazkepa by both the U.S. Food and Drug Administration (FDA) in 2019 and the European Medicines Agency (EMA) in 2021 for cardiovascular risk reduction in statin-treated patients with elevated triglycerides.
Several large trials of mixed EPA/DHA omega-3 supplements (including STRENGTH and VITAL) failed to show significant cardiovascular benefit. Researchers have proposed several explanations: Vazkepa uses purified EPA only (not EPA+DHA), at a higher dose, in a higher-risk population, and DHA may actually counteract some of EPA's beneficial effects on lipoproteins and inflammation. Additionally, the mineral oil placebo used in REDUCE-IT has been debated, though sensitivity analyses have largely supported the robustness of the results.
Frequently Asked Questions About Vazkepa
Vazkepa (icosapent ethyl) is used together with a statin to reduce the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with elevated triglycerides who already have cardiovascular disease or diabetes with additional risk factors. It is not used simply to lower triglycerides, but specifically to reduce cardiovascular risk in high-risk patients already on statin therapy.
Vazkepa contains a single, highly purified omega-3 fatty acid (EPA/icosapent ethyl) at pharmaceutical-grade purity, unlike over-the-counter fish oil supplements which contain a mixture of EPA and DHA at lower purities. The REDUCE-IT trial demonstrated that Vazkepa significantly reduces cardiovascular events by 25%, while large-scale studies of mixed EPA/DHA supplements (STRENGTH, VITAL) have not shown the same cardiovascular benefit. Vazkepa is a prescription medicine manufactured under strict pharmaceutical quality standards.
If you are allergic to fish or shellfish, speak with your doctor before taking Vazkepa, as it is derived from fish oil. Your doctor will carefully assess whether the potential cardiovascular benefits outweigh the risk of allergic reaction. Importantly, Vazkepa also contains soy lecithin, so it must not be used by anyone with a soy or peanut allergy. Patients with known fish allergies who start Vazkepa may be monitored more closely for signs of hypersensitivity.
No, Vazkepa does not replace statins. It is specifically designed to be used as an add-on therapy alongside a statin. The cardiovascular benefits demonstrated in the REDUCE-IT trial were observed in patients who were already taking maximally tolerated statin therapy. You should continue taking your statin as prescribed by your doctor. The combination of statin plus Vazkepa addresses different aspects of cardiovascular risk: statins primarily lower LDL cholesterol, while Vazkepa provides additional protection through triglyceride reduction, anti-inflammatory effects, and plaque stabilization.
Yes, atrial fibrillation (AF) and atrial flutter are recognized side effects of Vazkepa, occurring in up to 1 in 10 patients (5.3% vs. 3.9% with placebo in REDUCE-IT). If you have a history of atrial fibrillation, your doctor will weigh the cardiovascular benefits of Vazkepa against this increased risk. Symptoms to watch for include palpitations, irregular heartbeat, dizziness, shortness of breath, or chest discomfort. Report any new or worsening heart rhythm symptoms to your doctor promptly.
The primary evidence comes from the REDUCE-IT trial, a landmark randomized controlled trial involving 8,179 patients followed for a median of 4.9 years. The trial demonstrated a 25% relative risk reduction in major adverse cardiovascular events when Vazkepa was added to statin therapy. Results were published in the New England Journal of Medicine in 2019 and have been incorporated into guidelines by the AHA/ACC and ESC. This level 1A evidence led to regulatory approval by both the FDA and EMA.
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- Bhatt DL, Steg PG, Miller M, et al. (2019). "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." New England Journal of Medicine. 380(1):11-22. The REDUCE-IT trial: landmark RCT demonstrating 25% cardiovascular risk reduction. Evidence level: 1A
- European Medicines Agency (EMA) (2021). "Vazkepa (icosapent ethyl) – Summary of Product Characteristics." Official European regulatory documentation for Vazkepa prescribing information.
- Mach F, Baigent C, Catapano AL, et al. (2020). "2019 ESC/EAS Guidelines for the management of dyslipidaemias." European Heart Journal. 41(1):111-188. European Society of Cardiology guidelines on lipid management including icosapent ethyl recommendations.
- Virani SS, Morris PB, Agarwala A, et al. (2021). "2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia." Journal of the American College of Cardiology. 78(9):960-993. American College of Cardiology guidance on icosapent ethyl use in hypertriglyceridemia.
- Bhatt DL, Steg PG, Miller M, et al. (2019). "Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT." Journal of the American College of Cardiology. 73(22):2791-2802. Analysis of total (first and recurrent) cardiovascular events in REDUCE-IT.
- Mason RP, Libby P, Bhatt DL (2020). "Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid." Arteriosclerosis, Thrombosis, and Vascular Biology. 40(4):802-814. Review of EPA's anti-inflammatory, antiplatelet, and plaque-stabilizing mechanisms.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in cardiology, pharmacology, internal medicine, and endocrinology.